pharmaceutical preparations
Company profile
Ticker
MNOV
Exchange
Website
CEO
Yuichi Iwaki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
MEDICINOVA JAPAN INC. • AVIGEN, INC • MEDICINOVA EUROPE GmbH ...
IRS number
330927979
MNOV stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Apr 24
10-K
2023 FY
Annual report
15 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q1
Quarterly report
9 Aug 23
8-K
Departure of Directors or Certain Officers
7 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 51.51 mm | 51.51 mm | 51.51 mm | 51.51 mm | 51.51 mm | 51.51 mm |
Cash burn (monthly) | 456.30 k | 83.33 k | 382.30 k | 886.78 k | 457.18 k | 911.59 k |
Cash used (since last report) | 3.12 mm | 569.81 k | 2.61 mm | 6.06 mm | 3.13 mm | 6.23 mm |
Cash remaining | 48.39 mm | 50.94 mm | 48.89 mm | 45.44 mm | 48.38 mm | 45.27 mm |
Runway (months of cash) | 106.0 | 611.3 | 127.9 | 51.2 | 105.8 | 49.7 |
Institutional ownership, Q2 2023
22.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 3 |
Closed positions | 8 |
Increased positions | 4 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 11.39 bn |
Total shares | 10.88 mm |
Total puts | 2.80 k |
Total calls | 32.70 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
3D Investment Partners Pte. | 5.50 mm | $14.25 mm |
Essex Woodlands Management | 1.11 mm | $2.54 bn |
BLK Blackrock | 731.37 k | $1.68 bn |
Vanguard | 616.84 k | $1.42 bn |
C Citigroup | 498.26 k | $1.15 bn |
Geode Capital Management | 437.25 k | $1.01 bn |
Millennium Management | 220.71 k | $507.62 mm |
JPM JPMorgan Chase & Co. | 168.21 k | $386.89 mm |
NTRS Northern Trust | 154.19 k | $354.63 mm |
Renaissance Technologies | 146.90 k | $338.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Jan 24 | Matsuda Kazuko | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 157,500 | 378.00 k | 157,500 |
9 Jan 24 | Iwaki Yuichi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 210,000 | 504.00 k | 210,000 |
9 Jan 24 | Geoffrey OBrien | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 84,000 | 201.60 k | 84,000 |
4 Aug 23 | Nicole Lemerond | Stock Option Common Stock | Grant | Acquire A | No | No | 2.47 | 18,333 | 45.28 k | 18,333 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
3 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Mar 24
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
27 Mar 24
Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
27 Mar 24
Press releases
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
2 Apr 24
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
26 Mar 24
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
20 Mar 24
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
12 Mar 24